Primary Gliosarcoma with Extracranial Metastasis

Choi, Min Gyu; Lee, Jehee; Lee, Min Seok; Suh, Sang Jun; Lee, Yoon Soo; Kang, Dong Gee

doi:10.14791/btrt.2020.8.e9

Cited by 9 publications

(6 citation statements)

References 13 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Extracranial dissemination of both tumors is very rare (0.5% of cases); GS has been described as having a greater propensity to metastasize, but mechanism behind this infrequent condition remains unclear. [ 4 , 19 ] Lung and pleural metastases have been estimated to occur in around 60%, followed by lymph nodes (50%). Liver and bone metastases (vertebrae 70%) are seen in approximately 30%.…”

Section: Discussionmentioning

confidence: 99%

Unusual extraneural metastasis of glioblastoma

Achi,

Veintimilla

et al. 2023

Surgical Neurology International

View full text Add to dashboard Cite

Background: Glioblastoma (GB) is the most common and aggressive malignant brain tumor in adults. Extracranial metastases are very rare, been described in the lungs, soft tissue, or the intraspinal space. Case Description: Through a PubMed-based bibliographic search, the authors reviewed the cases reported in the literature to date, emphasizing the epidemiology and pathophysiology of this rare condition. A clinical case of a 46-year-old man with an initial diagnosis of gliosarcoma, who received complete surgical and adjuvant treatment and later recurred as GB with incidental finding of a lung tumor, whose pathology reported metastasis of the primary, is illustrated. Conclusion: Understanding the pathophysiology, it is likely that the incidence of extraneural metastases may continue to increase. Considering improvements in diagnostic techniques that allow early diagnosis, as well as advances in neurosurgical therapy and multimodal management with the aim of improving patient survival, the period in which malignant cells can spread and form extracranial metastases could increase. When screening should be performed to detect metastases in these patients is still not clear. The neuro-oncologists should pay attention to the systematic survey for extraneural metastasis of the GB. Timely detection and early treatment improve overall quality of patients’ life.

show abstract

Section: Discussionmentioning

confidence: 99%

Unusual extraneural metastasis of glioblastoma

Achi,

Veintimilla

et al. 2023

Surgical Neurology International

View full text Add to dashboard Cite

show abstract

“…Analysis of the abstract/full-text of these 165 articles was performed, including collection of the molecular testing information. To investigate the molecular characterization of GBM with extraneural metastasis, 35 full-text articles32,36,38–70 reporting a total of 42 cases that had data from molecular genetic testing or IHC analysis for IDH1 R132H/p53 were analyzed. Pertinent clinical information, including age, sex, timeline of disease course, follow-up, and molecular/immunophenotypic profiling were extracted from the 35 publications.…”

Section: Methodsmentioning

confidence: 99%

TP53 Mutation and Extraneural Metastasis of Glioblastoma

Zhang¹,

Katsakhyan²,

LiVolsi³

et al. 2021

American Journal of Surgical Pathology

View full text Add to dashboard Cite

Extraneural metastases of glioblastoma (GBM), although rare, are becoming an increasingly recognized occurrence. Currently, the biological mechanism underlying this rare occurrence is not understood. To explore the potential genomic drivers of extraneural metastasis in GBM, we present the molecular features of 4 extraneural metastatic GBMs, along with a comprehensive review and analysis of previously reported cases that had available molecular characterization. In addition to our 4 cases, 42 patients from 35 publications are reviewed. To compare the molecular profiles between GBM cases with extraneural metastasis and the general GBM population, genomic data from GBM samples in The Cancer Genome Atlas (TCGA) database were also analyzed. We found that 64.5% (20/31) of the cases with extraneural metastasis that were tested for TP53 changes had at least 1 TP53 pathogenic variant detected in either 1 or both primary and metastatic tumors. In contrast, TP53 mutation was significantly less frequent in the unselected GBM from TCGA (22.6%, 56/248) (P=0.000). In addition, O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation was more common in unselected TCGA GBM cases (48.6%, 170/350) than in cases with extraneural metastasis (31.8%, 7/22), although not statistically significant. Although isocitrate dehydrogenase (IDH) mutation is a rare occurrence in high-grade astrocytomas, IDH-mutant grade 4 astrocytomas are at least as likely to metastasize as IDH wild-type GBMs; 3 metastatic cases definitively harbored an IDH1 (p.R132H) mutation in our analysis. Our findings not only provide potential biomarkers for earlier screening of extraneural metastasis, but could also suggest clues to understanding biological mechanisms underlying GBM metastasis, and for the development of therapeutic modalities.

show abstract

“…A rare form, with only about 200 case reports, of high-grade glioma that has both glioblastoma and sarcoma components and is more prone to extracranial metastasis than other gliomas, is gliosarcoma [106]. Although it is an extremely rare neoplasm, over the years several attempts to characterize gliosarcoma, either alone, or in comparison with GBM were undertaken [154][155][156][157][158][159][160]. As with GBM, the poor prognosis with a median survival of about nine months, and the failure of gliosarcoma treatment, are due to the tumor aggressiveness, which causes extensive infiltration of the tumoral cells into the surrounding healthy brain tissue.…”

Section: Malignant Tumorsmentioning

confidence: 99%

Advances in Mass Spectrometry of Gangliosides Expressed in Brain Cancers

Biricioiu,

Sarbu,

Ica

et al. 2024

IJMS

View full text Add to dashboard Cite

Gangliosides are highly abundant in the human brain where they are involved in major biological events. In brain cancers, alterations of ganglioside pattern occur, some of which being correlated with neoplastic transformation, while others with tumor proliferation. Of all techniques, mass spectrometry (MS) has proven to be one of the most effective in gangliosidomics, due to its ability to characterize heterogeneous mixtures and discover species with biomarker value. This review highlights the most significant achievements of MS in the analysis of gangliosides in human brain cancers. The first part presents the latest state of MS development in the discovery of ganglioside markers in primary brain tumors, with a particular emphasis on the ion mobility separation (IMS) MS and its contribution to the elucidation of the gangliosidome associated with aggressive tumors. The second part is focused on MS of gangliosides in brain metastases, highlighting the ability of matrix-assisted laser desorption/ionization (MALDI)-MS, microfluidics-MS and tandem MS to decipher and structurally characterize species involved in the metastatic process. In the end, several conclusions and perspectives are presented, among which the need for development of reliable software and a user-friendly structural database as a search platform in brain tumor diagnostics.

show abstract

Primary Gliosarcoma with Extracranial Metastasis

Cited by 9 publications

References 13 publications

Unusual extraneural metastasis of glioblastoma

Unusual extraneural metastasis of glioblastoma

TP53 Mutation and Extraneural Metastasis of Glioblastoma

Advances in Mass Spectrometry of Gangliosides Expressed in Brain Cancers

Contact Info

Product

Resources

About